Drug Profile
Research programme: cancer immunotherapeutics - Alligator Biosciences
Alternative Names: IMCANLatest Information Update: 28 Feb 2018
Price :
$50
*
At a glance
- Originator Alligator Bioscience
- Class Monoclonal antibodies
- Mechanism of Action CD40 antigen stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Feb 2018 No recent reports of development identified for preclinical development in Cancer in Sweden (Intratumoural, Injection)
- 06 Feb 2015 Alligator Bioscience plans a phase I trial for Solid tumours (Late-stage disease) in United Kingdom, Denmark, Sweden (NCT02379741)
- 14 Jan 2014 Preclinical trials in Cancer in Sweden (Intratumoural) before Jan 2014